Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:1338- 1347.

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.

Trial profile Fox K et al. Lancet 2008;372:

Trial Identification, Inclusion, and Exclusion Krista M. Dale et al, JAMA. 2006; 295:

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

Vitamins B, E, and Health Partha Paul Endocrinology Rounds.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Clinical Outcomes with Newer Antihyperglycemic Agents

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

VBWG HOPE-TOO: Results of the HOPE Study Extension.

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.

Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Slide Source Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.

Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.

HOPE: Heart Outcomes Prevention Evaluation study

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

The Chemical Differences Between EPA and DHA.

Baseline characteristics of patients

TNT Study: Baseline Characteristics of the Patients

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

Aspirin and Cardioprevention in 2018

Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2 Robert N. Foley, Charles A. Herzog, Allan.

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Baseline Characteristics by Baseline N-BNP Level

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Berger JS, et al. JAMA 2009;301:

Heart Protection Study Collaborative Group Lancet 2011;377:469-76

Estimated 5-year rate of a first major vascular event (MVE), major coronary event (MCE),or vascular death in univariate and multivariate risk subgroups.

Flow of Patients Through Trial

Baseline Characteristics of the Study Participants

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Emerging Risk Factors Collaboration. JAMA 2009;302:412-23

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Baseline Characteristics of the Patients – Part I

Baseline Characteristics by hs-CRP

The ACCORD Study Group. NEJM 2010; Epub March 14

Baseline Characteristics of the Patients - Part I

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

The ACCORD Study Group. NEJM 2010; Epub March 14

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Presentation transcript:

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Baseline Characteristics of All HOPE Study Patients and of the Patients at Centers Continuing in the Trial Extension (HOPE-TOO) The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Incidence and Relative Risks of Cancers and Deaths Due to Cancer The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Kaplan-Meier Analysis of the Effects of Vitamin E on Incident Cancer and Major Cardiovascular Events for All 9541 Study Patients The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Incidence and Relative Risks of Site-Specific Cancers The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Incidence and Relative Risks of Major Vascular Events, Deaths, and Secondary Cardiovascular Outcomes The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Kaplan-Meier Analysis of the Effects of Vitamin E on All Heart Failure Events and Hospital Admissions for Heart Failure in HOPE and HOPE-TOO Patients The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Lung Cancer in Large Randomized Trials of Vitamin E The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293: